Accessibility Menu
Novo Integrated Sciences logo

Novo Integrated Sciences(OTC) NVOS

Market Cap$73.00KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-100%
5 Year-100%
1 Year+1,750%
1 Month+6%
$0.00
+5.71%
+0.00Today
Novo Integrated Sciences last closing stock price
MetricPriceDate
Last closeUSD 0.002026-07-28
Novo Integrated Sciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-7.5%USD 0.002026-07-21
1 month+5.71%USD 0.002026-06-26
3 month+19.35%USD 0.002026-04-29
Year to date+37.04%USD 0.002025-12-31
1 year+1,750%USD 0.002025-07-28
3 year-99.66%USD 1.102023-07-28
5 year-99.98%USD 18.802021-07-29
Since inception-100%USD 84.002017-05-10

Novo Integrated Sciences Financials at a Glance

Market Cap

$73.00KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$13.29M

Net Income (TTM)

-$16.17M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-8.42 (Low)

Price

$0.00

Volume

297

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.06

Estimated Earnings Date

Jul 21, 2025

NVOS News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Novo Integrated Sciences

Novo Integrated Sciences, Inc. is a healthcare company that provides a wide range of primary healthcare services and products. The company operates through two main segments: Healthcare Services and Product Manufacturing and Development, focusing on innovative therapeutic approaches and wellness solutions.

Products and Services
  • Comprehensive healthcare services including physiotherapy, chiropractic care, and occupational therapy
  • Specialized treatments such as acupuncture, functional dry needling, and advanced rehabilitation
  • Telemedicine consultations and remote patient monitoring for enhanced patient care
Growth Outlook
  • Recent quarterly revenue reached $3.08 million, indicating strong service demand
  • Gross profit margin improved to 51.2% in the latest quarter, showcasing operational efficiency
  • Expansion plans include increasing the number of clinics to enhance service accessibility
Financial Highlights
  • Trailing twelve months revenue totaled $12.5 million, reflecting a solid growth trajectory
  • Net income for the latest quarter was $5.0 million, a significant turnaround from previous losses
  • Cash and cash equivalents stood at $844,584, providing liquidity for operational needs
Novo Integrated Sciences, Inc. is positioned in the healthcare sector, focusing on delivering quality services across various demographics. The company’s diverse offerings cater to a wide range of health needs, from pediatric to geriatric care. Recent financial performance indicates a positive trend, with increasing revenues and improved profit margins. The strategic focus on expanding clinic locations and enhancing service delivery through technology positions the company for future growth. Investors may find the company's commitment to innovative healthcare solutions and operational improvements appealing as it navigates the evolving healthcare landscape.
AI Generated • Jul 10, 2026

Industry

Healthcare Providers and Services

Employees

264

CEO

Robert Mattacchione

Headquarters

Bellevue, WA 98004, US

NVOS Financials

Key Financial Metrics (TTM)

Gross Margin

43.20%

Operating Margin

-62.54%

Net Income Margin

-121.32%

Return on Equity

-81.23%

Return on Capital

-42.41%

Return on Assets

-50.18%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$73.00KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

19.73M

Volume

297

Avg. Volume

6.62K

Financials (TTM)

Gross Profit

$5.74M

Operating Income

-$8.31M

EBITDA

-$6.64M

Operating Cash Flow

-$5.07M

Capital Expenditure

-$5.04K

Free Cash Flow

-$5.07M

Cash & ST Invst.

$844.58K

Total Debt

$4.71M

Novo Integrated Sciences Performance Analysis

Novo Integrated Sciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-08-31USD 9,305,255N/A
20222022-08-31USD 11,737,93726.1%
20232023-08-31USD 12,572,0197.1%
20242024-08-31USD 13,294,3575.7%
Novo Integrated Sciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12023-11-3017.8%
Q22024-02-29-18.5%
Q32024-05-31-0.6%
Q42024-08-31-2.3%
Novo Integrated Sciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-08-31USD -1.80N/A
20222022-08-31USD -11.28526.3%
20232023-08-31USD -1.30-88.5%
20242024-08-31USD -0.90-31.0%
Novo Integrated Sciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12023-11-30-40.0%
Q22024-02-2942.9%
Q32024-05-31-362.5%
Q42024-08-31135.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2024YOY CHG

Revenue

$3.08M

-6.7%

Gross Profit

$1.58M

+70.0%

Gross Margin

51.21%

N/A

Market Cap

$73.00KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$634.78

N/A

Employees

115

N/A

Net Income

$5.00M

+258.3%

EBITDA

$7.25M

+440.7%

Quarterly Fundamentals

Name
Q4 2024YOY CHG

Total Cash

$844.58K

+102.9%

Total Debt

$4.71M

+5.3%

Accounts Receivable

$3.15M

+114.9%

Inventory

$1.00M

-9.6%

Long Term Debt

$2.99M

+70.2%

Short Term Debt

$3.16M

+16.4%

Return on Assets

-50.18%

N/A

Return on Invested Capital

-47.34%

N/A

Free Cash Flow

-$548.95K

-111.8%

Operating Cash Flow

-$545.92K

-138.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PBLAPanbela Therapeutics, Inc.
$0.01+0.00%
BBBTBlack Bird Biotech, Inc.
$0.00+0.00%
SETOSETO Holdings, Inc.
$0.01+0.00%
OMHEOMNI Health, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOFISoFi Technologies
$15.25-0.09%
INTCIntel
$81.88-0.05%
NVDANvidia
$190.01-0.04%
TQQQProShares Trust - ProShares UltraPro Qqq
$57.75-0.06%

Questions About NVOS

What is the current price of Novo Integrated Sciences?

Novo Integrated Sciences is trading at $0.00 per share.

What is the 52-week range for Novo Integrated Sciences?

Over the past 52 weeks, Novo Integrated Sciences has traded between $0.00 and $0.06.

How much debt does Novo Integrated Sciences have?

As of the most recent reporting period, Novo Integrated Sciences reported total debt of $5.98M.

How much cash does Novo Integrated Sciences have on hand?

Novo Integrated Sciences reported $844.58K in cash and cash equivalents in its most recent financial results.

What is Novo Integrated Sciences’s dividend yield?

Novo Integrated Sciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.